{"title":"我们的2型糖尿病患者有足够的保护免受心肾并发症吗?","authors":"AProf Goh Su-Yen","doi":"10.33591/sfp.47.8.u1","DOIUrl":null,"url":null,"abstract":"Cardiovascular and renal outcome trials categorically demonstrate the benefits of SGLT2 inhibitors (SGLT2i). Various pharmacotherapy algorithms recommend early use of SGLT2i, especially among those with existing cardiovascular disease, heart failure, or kidney disease. Despite a widening spectrum of patient eligibility, treatment gaps and clinical inertia still exist.","PeriodicalId":85774,"journal":{"name":"The Singapore family physician","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Are Our Type 2 Diabetes Patients Sufficiently Protected from Cardiorenal Complications?\",\"authors\":\"AProf Goh Su-Yen\",\"doi\":\"10.33591/sfp.47.8.u1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiovascular and renal outcome trials categorically demonstrate the benefits of SGLT2 inhibitors (SGLT2i). Various pharmacotherapy algorithms recommend early use of SGLT2i, especially among those with existing cardiovascular disease, heart failure, or kidney disease. Despite a widening spectrum of patient eligibility, treatment gaps and clinical inertia still exist.\",\"PeriodicalId\":85774,\"journal\":{\"name\":\"The Singapore family physician\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Singapore family physician\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33591/sfp.47.8.u1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Singapore family physician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33591/sfp.47.8.u1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Are Our Type 2 Diabetes Patients Sufficiently Protected from Cardiorenal Complications?
Cardiovascular and renal outcome trials categorically demonstrate the benefits of SGLT2 inhibitors (SGLT2i). Various pharmacotherapy algorithms recommend early use of SGLT2i, especially among those with existing cardiovascular disease, heart failure, or kidney disease. Despite a widening spectrum of patient eligibility, treatment gaps and clinical inertia still exist.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
